Assessing Dermatologic Responses to Amivantamab in EGFR-Mutated NSCLC
The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.
Sequencing Bispecifics and CAR T-Cell Therapy in R/R Multiple Myeloma
A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.
Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma
Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.
